Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
101.35
-3.65 (-3.48%)
At close: May 8, 2026, 4:00 PM EDT
103.00
+1.65 (1.63%)
After-hours: May 8, 2026, 7:58 PM EDT
Insmed Employees
Insmed had 1,664 employees as of December 31, 2025. The number of employees increased by 393 or 30.92% compared to the previous year.
Employees
1,664
Change (1Y)
393
Growth (1Y)
30.92%
Revenue / Employee
$492,526
Profits / Employee
-$711,391
Market Cap
21.97B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,664 | 393 | 30.92% |
| Dec 31, 2024 | 1,271 | 359 | 39.36% |
| Dec 31, 2023 | 912 | 176 | 23.91% |
| Dec 31, 2022 | 736 | 123 | 20.07% |
| Dec 31, 2021 | 613 | 92 | 17.66% |
| Dec 31, 2020 | 521 | 86 | 19.77% |
| Dec 31, 2019 | 435 | 62 | 16.62% |
| Dec 31, 2018 | 373 | 159 | 74.30% |
| Dec 31, 2017 | 214 | 53 | 32.92% |
| Dec 31, 2016 | 161 | 36 | 28.80% |
| Dec 31, 2015 | 125 | 36 | 40.45% |
| Dec 31, 2014 | 89 | 28 | 45.90% |
| Dec 31, 2013 | 61 | 20 | 48.78% |
| Dec 31, 2012 | 41 | -1 | -2.38% |
| Dec 31, 2011 | 42 | 2 | 5.00% |
| Dec 31, 2010 | 40 | 25 | 166.67% |
| Dec 31, 2009 | 15 | -82 | -84.54% |
| Dec 31, 2008 | 97 | 3 | 3.19% |
| Dec 31, 2007 | 94 | -63 | -40.13% |
| Dec 31, 2006 | 157 | 72 | 84.71% |
| Dec 31, 2005 | 85 | 30 | 54.55% |
| Dec 31, 2004 | 55 | 35 | 175.00% |
| Dec 31, 2003 | 20 | -3 | -13.04% |
| Dec 31, 2002 | 23 | -37 | -61.67% |
| Dec 31, 2001 | 60 | 20 | 50.00% |
| Dec 31, 2000 | 40 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Genmab | 2,973 |
| Jazz Pharmaceuticals | 2,890 |
| Incyte | 2,844 |
| Ascendis Pharma | 1,189 |
| Revolution Medicines | 883 |
INSM News
- 1 day ago - Insmed earnings selloff a buying opportunity, says H.C. Wainwright - TheFly
- 2 days ago - Insmed price target lowered to $185 from $200 at Raymond James - TheFly
- 2 days ago - Insmed price target lowered to $226 from $230 at Guggenheim - TheFly
- 2 days ago - Insmed price target lowered to $160 from $177 at Wells Fargo - TheFly
- 2 days ago - Insmed pullback a buying opportunity, says Roth Capital - TheFly
- 3 days ago - Insmed reports Q1 EPS (76c), consensus ($1.00) - TheFly
- 3 days ago - Insmed Earnings Call Transcript: Q1 2026 - Transcripts
- 3 days ago - Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update - PRNewsWire